Bionomics Limited Short Interest Up 278.6 percent in January
| BNOX Stock | USD 0.28 0.01 3.45% |
Slightly above 62% of Bionomics' investor base is looking to short. The analysis of the overall investor sentiment regarding Bionomics Ltd ADR suggests that many traders are alarmed. Bionomics' investing sentiment can be driven by a variety of factors including economic data, Bionomics' earnings reports, geopolitical events, and overall market trends.
Bionomics |
Bionomics Limited was the target of a significant growth in short interest in January. As of January 31st, there was short interest totalling 5,300 shares, a growth of 278.6 percent from the January 15th total of 1,400 shares. Based on an average daily volume of 10,100 shares, the short-interest ratio is currently
Read at thelincolnianonline.com
 |
Bionomics Fundamental Analysis
We analyze Bionomics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bionomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bionomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Bionomics is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Bionomics ADR Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bionomics stock to make a market-neutral strategy. Peer analysis of Bionomics could also be used in its relative valuation, which is a method of valuing Bionomics by comparing valuation metrics with similar companies.
Peers
Bionomics Related Equities
| ACRV | Acrivon Therapeutics, | 9.31 | ||||
| ACUT | Accustem Sciences | 9.09 | ||||
| ANTX | AN2 Therapeutics | 3.73 | ||||
| ADAG | Adagene | 3.65 | ||||
| AVTE | Aerovate Therapeutics | 0.75 | ||||
| RZLT | Rezolute | 1.02 | ||||
| PMVP | Pmv Pharmaceuticals | 1.24 | ||||
| SPRC | Scisparc | 4.00 | ||||
| ANEB | Anebulo Pharmaceuticals | 4.11 |
Additional Tools for Bionomics Stock Analysis
When running Bionomics' price analysis, check to measure Bionomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionomics is operating at the current time. Most of Bionomics' value examination focuses on studying past and present price action to predict the probability of Bionomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionomics' price. Additionally, you may evaluate how the addition of Bionomics to your portfolios can decrease your overall portfolio volatility.